Literature DB >> 32576710

Besides population age structure, health and other demographic factors can contribute to understanding the COVID-19 burden.

Marília R Nepomuceno1, Enrique Acosta2, Diego Alburez-Gutierrez3, José Manuel Aburto4,5,6, Alain Gagnon7,8, Cássio M Turra9.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32576710      PMCID: PMC7322063          DOI: 10.1073/pnas.2008760117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


× No keyword cloud information.
An insightful paper by Dowd et al. (1) highlights the importance of demography for analyzing coronavirus disease 2019 (COVID-19)–related mortality. The authors underscore the role of population age structure and intergenerational contacts for understanding differences in cross-country fatality and estimate the potential impact of the pandemic on different populations, acknowledging the need for additional information on the prevalence of comorbidities. We aim to interpret the proposed scenarios considering the widely different prevalence of chronic conditions by age in three of the countries discussed in the original paper. We argue that the burden of chronic diseases has the potential to offset the possible benefits of younger populations with different epidemiological characteristics. Age is fundamental to understanding differences in mortality risks. Indeed, age is a marker of the gradual accumulation of permanent damage over the life course and, consequently, is highly associated with chronic diseases and disabilities (2–4). Epidemiologic, social, and built environments amplify this association. As a result, the prevalence of chronic diseases at any given age can be expected to differ substantially in high-, low-, and middle-income settings. Since there is evidence that individuals with preexisting chronic conditions are at an increased risk of severe COVID-19 disease (5–8), it is essential to understand age-related health differences with respect to these conditions to shed light on the COVID-19 burden across countries. Dowd et al. (1) applied the estimated age-specific case-fatality rates of COVID-19 from Italy to younger—and less healthy—populations. By doing this, they implicitly assumed that the age prevalence of underlying comorbidities is similar in Italy, Brazil, and Nigeria. However, these populations have very different epidemiological profiles. Fig. 1 shows the ratios of the age-specific prevalence of underlying comorbidities of Brazil and Nigeria with respect to Italy using the Global Burden of Disease database (9) for cardiovascular disease, chronic obstructive pulmonary disease (COPD), and chronic kidney disease, health conditions most frequently observed in deaths and hospitalization from COVID-19 (5–8). Relative to Italy, the prevalence of chronic kidney and COPD in Brazil and Nigeria is considerably greater at most ages. Brazil and Nigeria have a substantially higher prevalence of cardiovascular diseases at adult ages but a lower prevalence at older ages.
Fig. 1.

Relative prevalence by health condition and age in Brazil and Nigeria compared to Italy: female and male, 2017. Source: ref. 9.

Relative prevalence by health condition and age in Brazil and Nigeria compared to Italy: female and male, 2017. Source: ref. 9. The influence of chronic disease prevalence on the steep age gradient to severe outcomes from COVID-19 is still unclear. If this influence is considerable, the differences across populations presented here suggest that younger individuals in low- and middle-income countries may be at a substantially higher risk of severe COVID-19 illness than individuals of the same age in high-income settings once age-related health conditions are considered. Demography science is not limited to the study of population distribution by age. Demographers can help elucidate other sources of between- and within-age variations in social distancing levels and infection, hospitalizations, and fatality rates as severe acute respiratory syndrome coronavirus 2 spreads in different settings. Besides chronic diseases, other potential factors include population density, household size and composition, hygienic and sanitary conditions, access to healthcare services, case notification systems, migration and displacement patterns, interregional inequalities, labor-market structure, economic disparities and welfare programs, endemic and other epidemic diseases, early-life conditions, epigenetic mechanisms, and immunosenescence.
  7 in total

1.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.

Authors:  Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos
Journal:  JAMA       Date:  2020-05-26       Impact factor: 56.272

Review 2.  Biomarkers related to aging in human populations.

Authors:  Eileen Crimmins; Sarinnapha Vasunilashorn; Jung Ki Kim; Dawn Alley
Journal:  Adv Clin Chem       Date:  2008       Impact factor: 5.394

3.  A duality in aging: the equivalence of mortality models based on radically different concepts.

Authors:  A I Yashin; J W Vaupel; I A Iachine
Journal:  Mech Ageing Dev       Date:  1994-05       Impact factor: 5.432

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  Demographic science aids in understanding the spread and fatality rates of COVID-19.

Authors:  Jennifer Beam Dowd; Liliana Andriano; David M Brazel; Valentina Rotondi; Per Block; Xuejie Ding; Yan Liu; Melinda C Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-16       Impact factor: 11.205

Review 6.  COVID-19 and Italy: what next?

Authors:  Andrea Remuzzi; Giuseppe Remuzzi
Journal:  Lancet       Date:  2020-03-13       Impact factor: 79.321

7.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  7 in total
  21 in total

1.  Excess Mortality During the COVID-19 Pandemic in Guatemala.

Authors:  Kevin Martinez-Folgar; Diego Alburez-Gutierrez; Alejandra Paniagua-Avila; Manuel Ramirez-Zea; Usama Bilal
Journal:  Am J Public Health       Date:  2021-09-23       Impact factor: 11.561

2.  Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa.

Authors:  Benjamin L Rice; Akshaya Annapragada; Rachel E Baker; Marjolein Bruijning; Winfred Dotse-Gborgbortsi; Keitly Mensah; Ian F Miller; Nkengafac Villyen Motaze; Antso Raherinandrasana; Malavika Rajeev; Julio Rakotonirina; Tanjona Ramiadantsoa; Fidisoa Rasambainarivo; Weiyu Yu; Bryan T Grenfell; Andrew J Tatem; C Jessica E Metcalf
Journal:  Nat Med       Date:  2021-02-02       Impact factor: 53.440

3.  Reply to Nepomuceno et al.: A renewed call for detailed social and demographic COVID-19 data from all countries.

Authors:  Jennifer Beam Dowd; Liliana Andriano; David M Brazel; Valentina Rotondi; Per Block; Xuejie Ding; Melinda C Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-23       Impact factor: 11.205

4.  Racial Disparities in Coronavirus Disease 2019 (COVID-19) Mortality Are Driven by Unequal Infection Risks.

Authors:  Jon Zelner; Rob Trangucci; Ramya Naraharisetti; Alex Cao; Ryan Malosh; Kelly Broen; Nina Masters; Paul Delamater
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

5.  Depression, Anxiety, and Lifestyle Among Essential Workers: A Web Survey From Brazil and Spain During the COVID-19 Pandemic.

Authors:  Raquel Brandini De Boni; Vicent Balanzá-Martínez; Jurema Correa Mota; Taiane De Azevedo Cardoso; Pedro Ballester; Beatriz Atienza-Carbonell; Francisco I Bastos; Flavio Kapczinski
Journal:  J Med Internet Res       Date:  2020-10-30       Impact factor: 5.428

6.  An investigation of risk factors of in-hospital death due to COVID-19: a case-control study in Rasht, Iran.

Authors:  Arsalan Salari; Marjan Mahdavi-Roshan; Zeinab Ghorbani; Seyede Sahere Mortazavi; Mona Naghshbandi; Farsima Faraghnia; Morteza Rahbar Taramsari; Zahra Ahmadnia
Journal:  Ir J Med Sci       Date:  2021-01-15       Impact factor: 1.568

Review 7.  Theoretical benefits of yogurt-derived bioactive peptides and probiotics in COVID-19 patients - A narrative review and hypotheses.

Authors:  Ahmed S Gouda; Fatima G Adbelruhman; Hamedah Sabbah Alenezi; Bruno Mégarbane
Journal:  Saudi J Biol Sci       Date:  2021-06-18       Impact factor: 4.052

8.  Genetic Hypothesis and Pharmacogenetics Side of Renin-Angiotensin-System in COVID-19.

Authors:  Donato Gemmati; Veronica Tisato
Journal:  Genes (Basel)       Date:  2020-09-03       Impact factor: 4.096

9.  Ecologic association between influenza and COVID-19 mortality rates in European countries.

Authors:  S Petti; B J Cowling
Journal:  Epidemiol Infect       Date:  2020-09-11       Impact factor: 2.451

10.  Monitoring trends and differences in COVID-19 case-fatality rates using decomposition methods: Contributions of age structure and age-specific fatality.

Authors:  Christian Dudel; Tim Riffe; Enrique Acosta; Alyson van Raalte; Cosmo Strozza; Mikko Myrskylä
Journal:  PLoS One       Date:  2020-09-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.